logo_immune

About the Company

Immune Pharmaceuticals, Inc. (NasdaqCM: IMNP) utilizes a personalized, bio-marker based approach to treating inflammatory diseases and cancer through the development of novel, targeted antibody therapeutics. Immune’s clinical candidate bertilimumab targets eotaxin-1, a mediator of inflammation. The candidate is in Phase II trials for ulcerative colitis and bullous pemphigoid, with data expected in late 2015 for BP and the first half 2016 for UC. Bertilimumab may have broad application across a range of disease states and Immune is exploring opportunities in nonalcoholic steatohepatitis (NASH) and severe eosinophilic asthma as well. The Company is developing AmiKet, an analgesic treatment for peripheral neuropathies, and is seeking a partner for Phase III trials and commercialization. Partnering of Amiket in 2015 could be a significant source of non-dilutive capital.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.


Recent Research